

Help prevent RSV-LRTI

Administer Beyfortus® to infants in their first or second RSV season¹

Infants in Alaska are at greater risk of severe RSV disease than those in the rest of the US^{2*}

The CDC recommends Beyfortus for all infants aged <8 months born during or entering their first RSV season and all American Indian and Alaska Native infants and children aged 8-19 months entering their second season.^{2,3†}

Beyfortus is available through the Vaccines for Children Program (VFC), the Alaska Vaccine Assessment Program (AVAP), and via private purchase.^{4,5‡}

IMMUNIZE and order Beyfortus
ELIGIBLE INFANTS throughout the year

CDC, Centers for Disease Control and Prevention; **RSV-LRTI**, respiratory syncytial virus lower respiratory tract infection.

*The typical RSV season in Alaska begins and ends later than in most other US states. The Alaska season starts in October or November, with peaks occurring midwinter from December to February and may last beyond March.^{3,4}

†Please refer to the full CDC recommendations.³

‡Based on available information from national payer organizations.

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Please see additional Important Safety Information on the following page and accompanying full Prescribing Information.

 **Beyfortus®** | 50 mg
(nirsevimab-alip) | 100 mg
Injection

Help protect infants against RSV disease with Beyfortus®¹

For the 2025-2026 RSV season, IHS guidance is for preferential use of Beyfortus for American Indian and Alaska Native eligible infants and children⁶

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

- **Hypersensitivity Reactions Including Anaphylaxis:** Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see accompanying full Prescribing Information.

Contact your wholesaler or distributor for further details on indirect ordering



IHS, Indian Health Service.

References: **1.** Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi. **2.** Lefferts B, Bressler S, Keck JW, et al. Nirsevimab effectiveness against medically attended respiratory syncytial virus illness and hospitalization among Alaska Native children—Yukon-Kuskokwim Delta region, Alaska, October 2023-June 2024. *MMWR Morb Mortal Wkly Rep.* 2024;73(45):1015-1021. **3.** RSV immunization guidance for infants and young children. Centers for Disease Control and Prevention. Updated August 18, 2025. Accessed September 24, 2025. <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html> **4.** Aho S, Ohlsen E. *RSV Immunization Guidance for the 2024-25 Season*. Bulletin No. 10. State of Alaska Epidemiology; September 13, 2024. Accessed September 24, 2025. https://epi.alaska.gov/bulletins/docs/b2024_10.pdf **5.** CDC's Vaccines for Children Program addendum: special considerations for COVID-19 vaccine and nirsevimab. Centers for Disease Control and Prevention. Updated March 29, 2024. Accessed September 24, 2025. https://www.cdc.gov/vaccines-for-children/media/pdfs/2024/08/operations-guide-covid-19-addendum-2024-4-2_002-508.pdf **6.** Indian Health Service. RSV monoclonal antibodies. US Department of Health and Human Services. August 2025. Accessed October 8, 2025. https://www.ihs.gov/sites/nptc/themes/responsive2017/display_objects/documents/guidance/NPTC-Formulary-Brief-RSV-FINAL.pdf

sanofi

1 Discovery Drive, Swiftwater, PA 18370
© 2025 Sanofi. All rights reserved.
MAT-US-2511517-v1.0-10/2025

 **Beyfortus®** | 50 mg
(nirsevimab-alip) | 100 mg
Injection